Short-Term And Long-Term Efficacy Of Bronchial Arterial Embolization Using Metallic Coils In The Management Of Hemoptysis

2011 ◽  
Author(s):  
masahiro kawashima ◽  
Kimihiko Masuda ◽  
Junichi Suzuki ◽  
Shinji Teramoto ◽  
Shinobu Akagawa
Keyword(s):  
Arterial Embolization ◽  
Short Term ◽  
Term Efficacy ◽  
Bronchial Arterial Embolization ◽  
Metallic Coils

scholarly journals Mycophenolate mofetil for Crohn's disease: short-term efficacy and long-term outcome

2004 ◽  
Vol 19 (4) ◽  
pp. 427-434 ◽  
Author(s):  
H. H. Wenzl ◽  
T. A. Hinterleitner ◽  
B. W. Aichbichler ◽  
P. Fickert ◽  
W. Petritsch
Keyword(s):  
Crohn’S Disease ◽  
Mycophenolate Mofetil ◽  
Crohn's Disease ◽  
Short Term ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Term Efficacy

scholarly journals Short-term and Long-term Efficacy of Oropharyngolaryngeal Strengthening Training on Voice Using a Mobile Healthcare Application in Elderly Women

2021 ◽  
Vol 26 (1) ◽  
pp. 219-230
Author(s):  
Nam-Bin Cho ◽  
Sung-Rae Cho ◽  
Seong Hee Choi ◽  
Heecheon You ◽  
Seok In Nam ◽  
...  
Keyword(s):  
Elderly Women ◽  
Short Term ◽  
Mobile Healthcare ◽  
Term Efficacy ◽  
Healthcare Application

Long-term efficacy of deep brain stimulation for essential tremor

Neurology ◽  
2019 ◽  
Vol 92 (12) ◽  
pp. e1378-e1386 ◽  
Author(s):  
Steffen Paschen ◽  
Julia Forstenpointner ◽  
Jos Becktepe ◽  
Sebastian Heinzel ◽  
Helge Hellriegel ◽  
...  
Keyword(s):  
Deep Brain Stimulation ◽  
Essential Tremor ◽  
Brain Stimulation ◽  
Rating Scale ◽  
Rebound Effect ◽  
Short Term ◽  
Term Efficacy ◽  
Secondary Outcomes ◽  
Deep Brain

ObjectiveDeep brain stimulation (DBS) of the ventral intermediate thalamic nucleus (Vim) is established for medically refractory severe essential tremor (ET), but long-term efficacy is controversial.MethodsTwenty patients with ET with DBS had standardized video-documented examinations at baseline, in the stimulation-on condition at short term (13.1 ± 1.9 months since surgery, mean ± SEM), and in the stimulator switched on and off (stim-ON/OFF) at long term; all assessments were done between 32 and 120 months (71.9 ± 6.9 months) after implantation. The primary outcome was the Tremor Rating Scale (TRS) blindly assessed by 2 trained movement disorder neurologists. Secondary outcomes were TRS subscores A, B, and C; Archimedes spiral score; and activities of daily living score. At long-term follow-up, tremor was additionally recorded with accelerometry. The rebound effect after switching the stimulator off was assessed for 1 hour in a subgroup.ResultsTremor severity worsened considerably over time in both in the nonstimulated and stimulated conditions. Vim-DBS improved the TRS in the short term and long term significantly. The spiral score and functional measures showed similar improvements. All changes were highly significant. However, the stimulation effect was negatively correlated with time since surgery (ρ = −0.78, p < 0.001). This was also true for the secondary outcomes. Only one-third of the patients had a rebound effect terminated 60 minutes after the stimulator was switched off. Long-term worsening of the TRS was more profound during stim-ON than in the stim-OFF condition, indicating habituation to stimulation.ConclusionVim-DBS loses efficacy over the long term. Efforts are needed to improve the long-term efficacy of Vim-DBS.Classification of evidenceThis study provides Class IV evidence that for patients with medically refractory severe ET, the efficacy of Vim-DBS severely decreases over 10 years.

scholarly journals Short- and Long-Term Efficacy of Hexadecylphosphocholine against Established Leishmania infantum Infection in BALB/c Mice

1998 ◽  
Vol 42 (3) ◽  
pp. 654-658 ◽  
Author(s):  
Yves Le Fichoux ◽  
Déborah Rousseau ◽  
Bernard Ferrua ◽  
Sandrine Ruette ◽  
Alain Lelièvre ◽  
...  
Keyword(s):  
Leishmania Infantum ◽  
Immunocompetent Host ◽  
Short Term ◽  
Fatal Disease ◽  
Promising Candidate ◽  
Term Efficacy ◽  
End Of Treatment ◽  
Immunosuppressed Patients ◽  
Short And Long Term

ABSTRACT In the immunocompetent host, visceral leishmaniasis (VL) is a fatal disease if untreated. In immunosuppressed patients, VL is an opportunistic infection for which there is no effective treatment for relapses. Here we report on the long-term activity of orally administered hexadecylphosphocholine (HDPC) against establishedLeishmania infantum infection in BALB/c mice. HDPC is a synthetic phospholipid with antiproliferative properties that has been extensively studied for its cancerostatic activity. Its short-term leishmanicidal effects in mice recently infected with viscerotropicLeishmania species have been previously reported. First, we show that 5 days of oral therapy with HDPC (20 mg/kg of body weight/day) led to amastigote suppression in the liver and the spleen of 94 and 78%, respectively (versus 85 and 55% suppression by meglumine antimonate in the liver and spleen, respectively), in mice infected 6 weeks before treatment and examined 3 days after the end of treatment. These results demonstrate the short-term efficacy of HDPC against an established Leishmania infection. Next, the long-term efficacy of HDPC was examined. In HDPC-treated mice both the hepatic and splenic amastigote loads were significantly reduced (at least 89%) 10, 31, and 52 days after the end of the treatment. In the treated mice, the increase of the splenic load was significantly slower than that in the untreated mice, demonstrating that the HDPC-exerted inhibition of Leishmania growth persisted for at least 7 to 8 weeks. Orally administered HDPC—the safe doses and side effects of which are at least partially known—appears to be a promising candidate for the treatment of VL.

Short-term efficacy and long-term survival of limited-stage small cell lung cancer treated with large fractionation radiotherapy and conventional fractionation radiotherapy.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e20586-e20586
Author(s):  
Cheng Chen ◽  
Yingying Jiang ◽  
Ning Jiang ◽  
Kang He ◽  
Cheng Chen ◽  
...  
Keyword(s):  
Survival Rate ◽  
Total Dose ◽  
Survival Benefit ◽  
Short Term ◽  
Term Survival ◽  
Long Term Survival ◽  
Conventional Fractionation ◽  
Term Efficacy ◽  
Significant Difference

e20586 Background: Hyperfractionation (1.5Gy per dose twice a day, total dose 45Gy) or conventional fractionation (2Gy per dose once a day, total dose 60-70Gy) is the recommended dose fractionation for LS-SCLC. However, the optimal segmentation mode and dose of radiotherapy have not been determined. In this study, we evaluated the short-term efficacy and toxic and side effects of macrofractionation to explore the feasibility of macrofractionation radiotherapy in the treatment of LS-SCLC patients. Methods: From May 2011 to February 2020, 52 patients with LS-SCLC admitted to Jiangsu Cancer Hospital were retrospectively analyzed. The patients were divided into two groups according to the dose separation mode, including 29 cases in the large division group (3-4Gy per dose once a day, total dose 45-60Gy) and 23 cases (2Gy per dose once a day, total dose 50-68Gy) in the conventional division group. The short-term efficacy, 1-year survival rate and some other aspects of the two groups were compared. Results: The short-term overall response rate of large segmentation group was 79.3%, and there was significant difference compared with 52.2% of conventional segmentation group ( χ2 =4.293, P<0. 05) (Table). The 1-year survival rate of the large segmentation group was similar to that of the conventional segmentation group (82.8% vs．82.6%). The median survival time of large segment group was 30 months,which was not significantly different from the 34 months of conventional segment group (χ2=0.417, P>0.05). In terms of the effect of the two fractionated dose modes on long survival, 31.0% of patients in the large fractionation group survived more than 48 months, compared with only 13% in the conventional fractionation group. In addition, in the subgroup analysis of this study, it was found that compared with conventional fractionation radiotherapy, patients aged 45-65 years with ECOG score of 0-1 and lesions less than 5cm before radiotherapy could obtain more significant survival benefit from large fractionation radiotherapy, with statistically significant difference between the two groups (χ2=4.874, P<0.05). Conclusions: Large segmentation radiotherapy in the treatment of patients with LS-SCLC can improve the therapeutic effect and prolong the survival, especially for patients aged 45-65 years with ECOG score of 0-1 and lesions less than 5cm before radiotherapy , the survival benefit is more significant. In addition, large fractionated radiotherapy showed certain advantages in the long-term survival of patients with LS-SCLC, which is worthy of further clinical application.[Table: see text]

scholarly journals Bipolar depression: a major unsolved challenge

2020 ◽  
Vol 8 (1) ◽  
Author(s):  
Ross J. Baldessarini ◽  
Gustavo H. Vázquez ◽  
Leonardo Tondo
Keyword(s):  
General Population ◽  
Psychiatric Disorders ◽  
Suicide Risk ◽  
Bipolar Depression ◽  
Unipolar Depression ◽  
Short Term ◽  
Term Efficacy ◽  
Medical Disorders ◽  
Mixed Features

AbstractDepression in bipolar disorder (BD) patients presents major clinical challenges. As the predominant psychopathology even in treated BD, depression is associated not only with excess morbidity, but also mortality from co-occurring general-medical disorders and high suicide risk. In BD, risks for medical disorders including diabetes or metabolic syndrome, and cardiovascular disorders, and associated mortality rates are several-times above those for the general population or with other psychiatric disorders. The SMR for suicide with BD reaches 20-times above general-population rates, and exceeds rates with other major psychiatric disorders. In BD, suicide is strongly associated with mixed (agitated-dysphoric) and depressive phases, time depressed, and hospitalization. Lithium may reduce suicide risk in BD; clozapine and ketamine require further testing. Treatment of bipolar depression is far less well investigated than unipolar depression, particularly for long-term prophylaxis. Short-term efficacy of antidepressants for bipolar depression remains controversial and they risk clinical worsening, especially in mixed states and with rapid-cycling. Evidence of efficacy of lithium and anticonvulsants for bipolar depression is very limited; lamotrigine has long-term benefit, but valproate and carbamazepine are inadequately tested and carry high teratogenic risks. Evidence is emerging of short-term efficacy of several modern antipsychotics (including cariprazine, lurasidone, olanzapine-fluoxetine, and quetiapine) for bipolar depression, including with mixed features, though they risk adverse metabolic and neurological effects.

Sign in / Sign up

Export Citation Format

Share Document